"Morpholines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D009025
|
| MeSH Number(s) |
D03.383.533.640
|
| Concept/Terms |
Morpholines- Morpholines
- Tetrahydro-1,4-Oxazines
- Tetrahydro 1,4 Oxazines
|
Below are MeSH descriptors whose meaning is more general than "Morpholines".
Below are MeSH descriptors whose meaning is more specific than "Morpholines".
This graph shows the total number of publications written about "Morpholines" by people in this website by year, and whether "Morpholines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 4 | 5 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 3 | 4 |
| 2003 | 2 | 10 | 12 |
| 2004 | 1 | 3 | 4 |
| 2005 | 0 | 6 | 6 |
| 2006 | 2 | 4 | 6 |
| 2007 | 3 | 1 | 4 |
| 2008 | 1 | 3 | 4 |
| 2009 | 1 | 4 | 5 |
| 2010 | 0 | 4 | 4 |
| 2011 | 3 | 3 | 6 |
| 2012 | 4 | 4 | 8 |
| 2013 | 1 | 5 | 6 |
| 2014 | 3 | 10 | 13 |
| 2015 | 3 | 9 | 12 |
| 2016 | 2 | 6 | 8 |
| 2017 | 4 | 4 | 8 |
| 2018 | 3 | 2 | 5 |
| 2019 | 3 | 1 | 4 |
| 2020 | 4 | 3 | 7 |
| 2021 | 4 | 5 | 9 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 0 | 1 |
| 2024 | 5 | 1 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Morpholines" by people in Profiles.
-
ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. JCI Insight. 2024 Oct 08; 9(19).
-
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024 Oct 24; 391(16):1486-1498.
-
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024 Apr; 25(4):474-487.
-
Expanding Complex Morpholines Using Systematic Chemical Diversity. Org Lett. 2024 May 03; 26(17):3493-3497.
-
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med. 2024 Mar; 30(3):716-729.
-
Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control. Cell Death Dis. 2024 01 22; 15(1):80.
-
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):105-121.
-
Inhibiting the IRE1a Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer. Adv Sci (Weinh). 2022 07; 9(21):e2105469.
-
Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation. JCO Precis Oncol. 2022 04; 6:e2100371.
-
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022 05; 33(5):522-533.